drugset
drugset / Trial / NCT05597020

A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

NCT05597020 ↗

Phase 4 Completed 60 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A study to find out if daridorexant is safe and efficacious in patients with insomnia and comorbid nocturia

Timeline

Start
2023-02-16
Primary completion
2024-04-12
Completion
2024-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral

Indications

insomnia